Page last updated: 2024-08-21

diphenylamine and Angiogenesis, Pathologic

diphenylamine has been researched along with Angiogenesis, Pathologic in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J1
Fukazawa, T; Ishida, N; Kato, K; Maeda, Y; Matsumoto, K; Naomoto, Y; Shimo, T; Takigawa, N; Whitsett, JA; Yamatsuji, T1
Barnard, J; Diaz-Montero, CM; Finke, JH; Lindner, DJ; Mao, FJ; Parker, Y; Pink, JJ; Rini, BI; Zamanian-Daryoush, M1

Other Studies

3 other study(ies) available for diphenylamine and Angiogenesis, Pathologic

ArticleYear
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2013
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
    Experimental cell research, 2015, Jul-15, Volume: 335, Issue:2

    Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coumarins; Diphenylamine; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Thiazoles; Xenograft Model Antitumor Assays

2015
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    British journal of cancer, 2016, 10-11, Volume: 115, Issue:8

    Topics: Adult; Animals; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrroles; Receptors, Interleukin-2; Sunitinib; Tumor Burden; Tumor Escape; Xenograft Model Antitumor Assays

2016